Biological analysis of rectal cancer samples

This study uses artificial intelligence to look for tiny signs of cancer left behind after treatment, which could help catch a return of the disease earlier. It involves giving blood samples over 6 months and possibly sharing a sample of your tumor tissue.

This study looks at patterns in the gut microbiome (gut bacteria) and gut chemicals (metabolites) to predict how rectal cancer may do after planned surgery. By understanding these markers, researchers hope to better forecast prognosis and tailor follow-up.

This study looks at stool samples to see whether gut bacteria or other microbes help explain why some rectal cancers respond less well to treatment given before surgery. If you have mid or lower rectal cancer and are planning pre-surgery treatment, your information and stool sample may help researchers improve how treatment is chosen.

This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.

This trial is studying a blood test (CTC) for people with rectal cancer that hasn't spread to other parts of the body. It aims to see how the test relates to treatment outcomes after surgery.

This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.